2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - La Nouvelle A-B
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Elderly
PAPER

420 Treatment sequencing after progression on bispecific antibody in relapsed/refractory multiple myeloma

Christoph Schaefers, MD, Shahzad Raza, MD2, Alexandria Jensen, Phd3, Ariel Grajales-Cruz, MD4, Timothy O'Brien, MD5, Murali Janakiram, MBBS6, Christopher J. Ferreri, MD7, Andrew J. Portuguese, MD8, Noa Biran, MD9, Cindy Varga, MD,BSc10, Poy Theprungsirikul, MD11, Omar Nadeem, MD12, Melinda Tan, MD13, Andre Corraes14, Lekha Mikkilineni, MD, MA15, Emily C. Liang, MD16, Masooma Shifa Rana, MBBS17, Binoy Yohannan, MD18, Darren Pan, MD19, Daniel Schrum20, Alissa Visram, MD, MPH21, Matias Eugenio Sanchez, MD22, Danai Dima, MD23, Rahul Banerjee, MD24, Sarvari V. Yellapragada, MD25, Bruno Almeida Costa, MD26, Megan M Herr, PhD27, Meera Mohan, MD, MS28, Faiz Anwer, MD29, Samer Al Hadidi, MD30, James A Davis, PharmD, BCOP31, Aimaz Afrough, MD32, Anthony Dominick33, Ariosto Siqueira Silva, PhD34, Omar Alexis Castaneda Puglianini, MD35, Doug W. Sborov, MD, MS36, Kelley Julian, PharmD, BCOP37, Francesca Cottini, MD38, Ashley Rosko, MD39, Jing Christine Ye, M.D., MSc40, Kenneth H. Shain, MD, PhD41, Melissa Alsina, MD42, Ajai Chari, MD43, Hira Mian, MD44, Nisha Joseph, MD45, Larry D Anderson Jr, MD, PhD46, Doris K. Hansen, MD47, Jack Khouri, MD48, Krina Patel Jr, MD, MSc49, Yi Lin Jr, MD, PhD50, Surbhi Sidana, MD51
1 Mayo Clinic, Rochester, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
10 Levine Cancer Institute/Atrium Health, Charlotte, North Carolina, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Stanford University School of Medicine, Stanford, California, United States
16 Fred Hutchinson Cancer Center, Seattle, Washington, United States
17 Stanford University School of Medicine, Stanford, California, United States
18 University of Minnesota, Minneapolis, Minnesota, United States
19 University of California San Francisco, San Francisco, California, United States
20 Duke Cancer Institute, Durham, North Carolina, United States
21 McMaster University, Hamilton, Ontario, Canada
22 University of Illinois Chicago, Chicago, Illinois, United States
23 Fred Hutchinson Cancer Center, Seattle, Washington, United States
24 Fred Hutchinson Cancer Center, Seattle, Washington, United States
25 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
26 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
27 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 Cleveland Clinic, Cleveland, Ohio, United States
30 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
31 Medical University of South Carolina, Charleston, South Carolina, United States
32 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
33 Medical University of South Carolina, Charleston, South Carolina, United States
34 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
35 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
36 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
37 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
38 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
39 The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
40 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
41 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
42 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
43 University of California San Francisco, San Francisco, California, United States
44 McMaster University, Hamilton, Ontario, Canada
45 Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, United States
46 Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, United States
47 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
48 Cleveland Clinic, Cleveland, Ohio, United States
49 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
50 Mayo Clinic, Rochester, United States
51 Stanford University School of Medicine, Stanford, California, United States

Bispecific antibodies (bsAb) are established in relapsed/refractory multiple myeloma (RRMM), but nearly all patients (pts) progress and treatment sequencing data after progression (PD) are limited. We examined efficacy of subsequent therapies after PD to bsAb and factors associated with response to subsequent therapies.

We retrospectively analyzed 1556 pts treated with an index bsAb (teclistamab, elranatamab, linvoseltamab, talquetamab) at 21 US Myeloma Immunotherapy Consortium Centers from 2022-2025. Pts starting a subsequent line (sLOT) after PD on index bsAb were included in the outcome analysis. Pts receiving bsAb as bridging were excluded. PFS/PFS-1/PFS-2 was defined from start of the index bsAb/1st sLOT/2nd sLOT to progression on that line or death from any cause. PFS was estimated by Kaplan-Meier with log-rank tests and median follow-up by reverse Kaplan-Meier. A multivariable Cox model for PFS-1 included PFS (<6 months, 6-12 months, >12 months), prior CAR T, index bsAb target, extramedullary disease (EMD) at PD, high-risk cytogenetics, functional high risk and next-line category.

Among a cohort of 1556 patients receiving BCMA- (73%, N=1142; teclistamab n=906, elranatamab n=220, linvoseltamab n=16), or GPRC5D- (27%, N=414; talquetamab) targeting index BsAb; 793 (51%) experienced progression. Of these 793 pts, 514 (64.8%) started a sLOT and 254/514 (49.4%) a 2nd sLOT. A third of pts (35%, 279/793) did not start a sLOT. Of these pts, 243 (87.1%) died with a median time from PD to death of 25.0 days (7.5, 60.0). Among the 514 with sLOT, median age at index bsAb initiation was 66.3 years with 6 prior LOT, 84.6% were triple-class refractory, 40.3% had IMS-IMWG high-risk, 20.4% EMD and 47.7% prior CAR T. Median follow-up was 9.1 and 10.0 mo for sLOT 1 and 2.

1st sLOT were bsAb (46.1%), polychemotherapy/alkylators (15.6%), anti-CD38/SLAMF7-based (8.9%) and IMiD/celmod-based (6.6%), BCL2-targeting (5.6%), selinexor (4.1%) and CAR T (3.9%) and others (9.1%). Among pts given a subsequent bsAb the target was switched in 168/176 (95.5%) after BCMA and in 53/57 (93%) after GPRC5D. CAR T followed BCMA/GPRC5D index in 1.8/8.1%. At 2nd sLOT, bsAb remained most frequent (32.7%), followed by anti-CD38/SLAMF7-based (14%), polychemotherapy/alkylators (11%), CAR T (9%) and IMiD/celmod-based (7.5%; other 25.6%).

Median PFS was 10.8 mo with a BCMA- and 8.3 mo with a GPRC5D-directed index bsAb. Median PFS-1 was 3.6 and PFS-2 3.0 mo. PFS (with index BsAB) > 12 months was associated with longer PFS-1, with median PFS-1 of 8.0, 5.0 and 3.0 mo for PFS>12, 6-12 and <6 mo. There was no statistical difference in PFS-1 based on type of sLOT (p=0.08), though it was numerically higher with subsequent CAR-T. Median PFS-1 across the categories was 10.5 mo with CAR T compared to 2.8 mo with BCMA bsAb, 4.2 mo with GPRC5D bsAb, 3.5 mo with aCD38/SLAMF7-Ab, 3.4 mo with IMiDs/celmods and 2.6 mo with polychemotherapy/alkylators. In the multivariable model, longer PFS was the best predictor for PFS-1, with HR for PFS-1 being 0.40 (95% CI 0.26 to 0.60, p<0.001) among pts with PFS >12mo vs <6mo. On this multivariable model, there was no statistically significant difference in PFS-1 amongst different categories of sLOT, though a trend was again noted for better PFS-1 with CAR-T (reference GPRC5D BsAb) with HR of 0.52 (95% CI 0.27 to 1.01; p=0.054).

Attrition after progression on a bsAb was substantial, one third of pts who progressed on a bsAb never received another line, so progression on a bsAb was frequently a terminal event. Retreatment with a bsAb was common and nearly always involved a target switch. PFS-1 and PFS-2 were shorter than PFS, while no differences in PFS-1 were noted based on treatment choice. Longer PFS was associated with longer PFS-1. Whether antigen expression or T-cell fitness at relapse identifies who still benefits from T-cell redirection was not assessed here but needs to be further explored. Relapse on bsAb identifies a population with substantial unmet need, greatest in early relapse, and studies evaluating new treatment options for this cohort are needed.

Christoph Schaefers, MD: Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Abbvie, Astra Zeneca, GSK, Janssen-Cilag, Sanofi, Takeda - Honoraria; Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony); Astra Zeneca, GSK, Janssen-Cilag, Menarini Stemline, oncopeptides, Pfizer, Regeneron - Consultancy (Includes expert testimony)